Search tips
Search criteria 


Logo of annrheumdAnnals of the Rheumatic DiseasesVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
Ann Rheum Dis. 2007 September; 66(9): 1266–1267.
PMCID: PMC1955148

The low‐penetrance R92Q mutation of the tumour necrosis factor superfamily 1A gene is neither a major risk factor for Wegener's granulomatosis nor multiple sclerosis

Inherited autosomal‐dominant mutations in the tumour necrosis factor receptor superfamily 1A (TNFRSF1A) gene encoding the tumour necrosis factor receptor p55 (TNF‐R1) are the cause of an auto‐inflammatory syndrome that is characterized by periodic fever attacks, aseptic peritonitis, arthritis, meningitis, conjunctivitis, pleuritis and skin rash (OMIM #142680). The most common TNFR‐associated periodic syndrome (TRAPS)‐like disease that is associated with a R92Q mutation, however, occurs sporadically, with later onset (median 23 years vs 7 years with other mutations) and a milder and often oligosymptomatic course.1,2 Intriguingly, carriers of the R92Q allele bear a slightly increased risk for some other diseases, such as myocardial infarction,3 increased carotid intima‐media thickness,3 thrombotic complications in Behcet's disease4 and early synovitis.1

Due to the low uncertain frequency of the R92Q allele in various ethnic populations (0.5–1%), the available data about multiple sclerosis (MS) patients5,6 do not exclude a possible risk of R92Q mutations being present. Recent case reports on small‐vessel vasculitis in patients with TNFRSF1A mutations (R92Q, T50M)7 and inflammatory manifestations of TNFRSF1A mutations in the central nervous system8 prompted us to investigate a possible mutual relationship between R92Q mutations, MS and Wegener's granulomatosis (WG) in the German population.

A total of 446 MS, 268 WG and 265 control cases (table 11)) were analysed for the presence of the R92Q allele by sequencing and NciI digestion of a PCR‐amplified segment (detailed information on request). Apart from the R92Q heterozygous mutation, we have not found other sequence variations in these patients that affect the extracellular domain of the TNF‐R1 receptor. Dinucleotide repeat length analysis performed in 15 R92Q+ patients from the MS and WG cohorts confirmed the sharing of an identical repeat length haplotype.9

Table thumbnail
Table 1 R92Q frequencies in MS and WG patients and in healthy controls

The odds ratios that we obtained (0.64 for MS and 0.91 for WG) do not indicate a significant association of the R92Q allele with these diseases. Although the confidence intervals are relatively large, the data permit us to exclude a more than 2‐fold risk of the R92Q allele in cases of WG and a more than 1.3‐fold risk for MS cases. As both the frequency and the remaining potential risk of the R92Q allele are indeed low, the impact of R92Q mutations on the MS and WG burden in the German population is negligibly small.

Considering the belief that, as yet unknown, susceptibility loci contribute to TRAPS‐like manifestations in R92Q carriers, we wondered if those genes that confer susceptibility to WG and MS convert the low‐penetrance status of the R92Q allele into a high‐penetrance condition. The clinical histories and archival records of those WG and MS patients that carried R92Q, however, did not provide evidence for preceding inflammatory episodes that are typical of TRAPS. Most strikingly, three WG patients suffered from recurrent serositis, which is highly uncommon in WG. Hence, recurrent serositis might be considered to be a manifestation of the R92Q allele on top of an unfolding WG.

With the reasonable assumption that the R92Q allele shows a 1% penetrance rate among the 4% carriers and, in view of the low prevalence of WG (50 per million) in the German population,10 it is extremely unlikely that both clinical phenotypes developed in a single patient just by coincidence. In the case of MS, such a casual coexistence of both clinical phenotypes is more likely as the prevalence of MS is about 30‐fold higher than that of WG.


The authors thank E. Stegmann and W. Essbauer for excellent technical assistance and H. Wekerle for his continuous interest in the project.


MS - multiple sclerosis

TNFRSF1A - tumour necrosis factor receptor superfamily 1A

TRAPS - TNFR‐associated periodic syndrome

WG - Wegener's granulomatosis


Supported by the German Research Council (DEJ, SFB571) and the state of Schleswig‐Holstein (PL, Innovationsfonds).

Competing interests: None declared.


1. Hull K M, Drewe E, Aksentijevich I, Singh H K, Wong K, McDermott E M. et al The TNF receptor‐associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore) 2002. 81349–368.368 [PubMed]
2. Ravet N, Rouaghe S, Dodé C, Bienvenu J, Stirnemann J, Lévy P. et al Clinical significance of P46L and R92Q substitutions in the tumour necrosis factor superfamily 1A gene. Ann Rheum Dis 2006. 651158–1162.1162 [PMC free article] [PubMed]
3. Poirier O, Nicaud V, Gariépy J, Courbon D, Elbaz A, Morrison C. et al Polymorphism R92Q of the tumour necrosis factor receptor 1 gene is associated with myocardial infarction and carotid intima‐media thickness—the ECTIM, AXA, EVA and GENIC Studies. Eur J Hum Genet 2004. 12213–219.219 [PubMed]
4. Amoura Z, Dodé C, Hue S, Caillat‐Zucman S, Bahram S, Delpech M. et al Association of the R92Q TNFRSF1A mutation and extracranial deep vein thrombosis in patients with Behcet's disease. Arthritis Rheum 2005. 52608–611.611 [PubMed]
5. Weinshenker B G, Hebrink D, Wingerchuk D M, Klein C J, Atkinson E, O'Brien P C. et al Genetic variants in the tumor necrosis factor receptor 1 gene in patients with MS. Neurology 1999. 521500–1503.1503 [PubMed]
6. Pras E, Aksentijevich I, Shinar Y, Kastner D L, Achiron A. Lack of evidence for an association between two genetic polymorphisms in the tumor necrosis factor receptor 1 gene and multiple sclerosis in Ashkenazi Jews. Eur Neurol 2001. 46153–155.155 [PubMed]
7. Lamprecht P, Moosig F, Adam‐Klages S, Mrowietz U, Csernok E, Kirrstetter M. et al Small vessel vasculitis and relapsing panniculitis in tumour necrosis factor receptor associated periodic syndrome (TRAPS). Ann Rheum Dis 2004. 631518–1520.1520 [PMC free article] [PubMed]
8. Minden K, Aganna E, McDermott M F, Zink A. Tumour necrosis factor receptor associated periodic syndrome (TRAPS) with central nervous system involvement. Ann Rheum Dis 2004. 631356–1357.1357 [PMC free article] [PubMed]
9. Eskdale J, Turestkaya R L, Armstrong C, Kuprash D V, Nedospasov S A, Gallagher G. et al A polymorphic microsatellite marker in the human p55 TNF receptor, CD120a. Genes Immunity 2000. 1228–230.230 [PubMed]
10. Reinhold‐Keller E, Herlyn K, Wagner‐Bastmeyer R, Gross W L. Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register. Arthritis Rheum 2005. 5393–99.99 [PubMed]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group